The use of afala in complex treatment of patients with chronic prostatitis improves the efficiency of therapy and prolongs its positive results. The preparation is well tolerated, has no contraindication, and can be combined with other drugs. Afala is indicated for patients with stages II and IIIa chronic prostatitis from the first day of therapy.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
E. V. Kul’chavenya, E. V. Brizhatyuk, and Yu. M. Kharlamova, Sib. Konsilium, No. 2, 11-14 (2005).
E. V. Kul’chavenya, E. V. Brizhatyuk, and Yu. M. Kharlamova, Vrachebnoe Soslovie, No. 6, 29-32 (2005).
D. W. Keetch, J. M. McMurty, D. S. Smith, et al., J. Urol., 156, No. 2, Pt. 1, 428-431 (1996).
R. S. Kirby, An Atlas of Prostatic Diseases. London (1999).
Author information
Authors and Affiliations
Additional information
Translated from Byulleten’ Eksperimental’noi Biologii i Meditsiny, Vol. 148, Suppl. 1, pp. 64-66, August, 2009
Rights and permissions
About this article
Cite this article
Kul’chavenya, E.V. Efficiency of Afala in Complex Therapy of Patients with Chronic Prostatitis. Bull Exp Biol Med 148, 315–317 (2009). https://doi.org/10.1007/s10517-009-0693-x
Received:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10517-009-0693-x